CL2020000940A1 - Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene. - Google Patents

Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene.

Info

Publication number
CL2020000940A1
CL2020000940A1 CL2020000940A CL2020000940A CL2020000940A1 CL 2020000940 A1 CL2020000940 A1 CL 2020000940A1 CL 2020000940 A CL2020000940 A CL 2020000940A CL 2020000940 A CL2020000940 A CL 2020000940A CL 2020000940 A1 CL2020000940 A1 CL 2020000940A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
new
phenylpyridine derivative
disclosure
phenylpyridine
Prior art date
Application number
CL2020000940A
Other languages
English (en)
Inventor
Wol-Young Kim
Jung-Eun Park
Keuk-Chan Bang
Joon-Seok Park
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of CL2020000940A1 publication Critical patent/CL2020000940A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE DIVULGACIÓN SE REFIERE A UN NUEVO DERIVADO DE FENILPIRIDINA REPRESENTADO POR LA FÓRMULA QUÍMICA 1 Y A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE EL MISMO, Y EL COMPUESTO SEGÚN LA PRESENTE DIVULGACIÓN PUEDE USARSE DE MANERA ÚTIL PARA LA PREVENCIÓN O EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNITARIAS O CÁNCERES.
CL2020000940A 2017-10-11 2020-04-07 Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene. CL2020000940A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170131349A KR102613433B1 (ko) 2017-10-11 2017-10-11 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
CL2020000940A1 true CL2020000940A1 (es) 2020-09-04

Family

ID=66101569

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000940A CL2020000940A1 (es) 2017-10-11 2020-04-07 Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene.

Country Status (23)

Country Link
US (1) US11149019B2 (es)
EP (1) EP3696176B1 (es)
JP (1) JP6876873B2 (es)
KR (2) KR102613433B1 (es)
CN (1) CN111212833B (es)
AU (1) AU2018349293B2 (es)
BR (1) BR112020007177A2 (es)
CA (1) CA3076667C (es)
CL (1) CL2020000940A1 (es)
CO (1) CO2020004319A2 (es)
DO (1) DOP2020000077A (es)
EC (1) ECSP20021379A (es)
ES (1) ES2915583T3 (es)
MA (1) MA50368A (es)
MX (1) MX2020003616A (es)
MY (1) MY194695A (es)
NZ (1) NZ763263A (es)
PH (1) PH12020550252A1 (es)
RU (1) RU2748945C1 (es)
SA (1) SA520411726B1 (es)
SG (1) SG11202002422WA (es)
TN (1) TN2020000050A1 (es)
WO (1) WO2019074275A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018348930A1 (en) 2017-10-11 2020-03-26 F. Hoffmann-La Roche Ag Bicyclic compounds for use as RIP 1 kinase inhibitors
KR102531088B1 (ko) * 2020-02-26 2023-05-10 주식회사 대웅제약 헤테로사이클릭아민 유도체의 제조 방법
WO2021172922A1 (ko) * 2020-02-26 2021-09-02 주식회사 대웅제약 헤테로사이클릭아민 유도체의 제조 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
EP1697508A2 (en) 2003-12-05 2006-09-06 Vertex Pharmaceuticals, Inc. Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof
WO2005066335A1 (en) 2003-12-30 2005-07-21 Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the interleukin-2-inducible cell kinase (itk) kinase domain
US7429605B2 (en) 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
TW200811134A (en) * 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
CA2683152A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
LT2975042T (lt) * 2010-06-23 2019-01-25 Hanmi Science Co., Ltd. Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui
AU2011272862A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
JP2015526520A (ja) 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
WO2014055934A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
KR102339228B1 (ko) 2013-08-23 2021-12-13 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
AU2014340318B2 (en) 2013-10-21 2019-01-17 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
US11311541B2 (en) 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Also Published As

Publication number Publication date
MX2020003616A (es) 2020-07-28
CN111212833B (zh) 2022-09-06
DOP2020000077A (es) 2020-08-15
WO2019074275A1 (ko) 2019-04-18
KR20220066012A (ko) 2022-05-23
JP6876873B2 (ja) 2021-05-26
SG11202002422WA (en) 2020-04-29
EP3696176A4 (en) 2021-03-17
EP3696176B1 (en) 2022-05-04
CN111212833A (zh) 2020-05-29
SA520411726B1 (ar) 2022-06-27
JP2020536093A (ja) 2020-12-10
CA3076667C (en) 2022-06-21
RU2748945C1 (ru) 2021-06-02
KR20190040773A (ko) 2019-04-19
BR112020007177A2 (pt) 2020-09-24
CO2020004319A2 (es) 2020-04-24
US20200223821A1 (en) 2020-07-16
MA50368A (fr) 2021-03-17
AU2018349293A1 (en) 2020-04-23
NZ763263A (en) 2023-02-24
PH12020550252A1 (en) 2021-02-22
AU2018349293B2 (en) 2020-10-08
CA3076667A1 (en) 2019-04-18
KR102613433B1 (ko) 2023-12-13
US11149019B2 (en) 2021-10-19
ES2915583T3 (es) 2022-06-23
ECSP20021379A (es) 2020-05-29
MY194695A (en) 2022-12-15
TN2020000050A1 (en) 2021-10-04
EP3696176A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
CL2020000940A1 (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene.
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
UA124329C2 (uk) Піримідинілоксибензольні похідні як гербіциди
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
MX2018015247A (es) Heterociclos de biarilmetilo.
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
EP3978477A3 (en) Materials for organic electroluminescent devices
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
BR112017008481A2 (pt) composto antimicótico
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
CY1123892T1 (el) Κρυσταλλικες μορφες του 6-((6,7-διμεθοξυκιναζολιν-4-υλο)οξυ)-ν,2-διμεθυλοβενζοφουρανο-3-καρβοξαμιδιου
BR112017002203A2 (pt) composição, processo para proteção de um material orgânico susceptível à degradação oxidativa, térmica ou induzida pela luz, uso de um composto de fórmula i-p, i-o ou i-m, e, composto
EA201691412A1 (ru) Гидроксиформамидные производные и их применение